本帖最后由 老马 于 2012-1-13 21:20 编辑 9 R. }; D# ?; _ Y* V2 {
& M) q7 G. k2 X) G6 V+ }6 j/ E5 b爱必妥和阿瓦斯丁的比较
4 K! S1 a) D [/ _% [$ T @# g
2 Z$ q- D8 o7 j E# f
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/9 h' p4 x! O. X Q0 R
# b; O3 r7 _' K9 g
7 A7 w6 J7 e. X4 Y. J/ G3 Chttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/7 |- T8 z. p- \" l& D; o+ h; w
==================================================
) O& A6 d" F1 w3 g4 S! sOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)' l# e* }9 x! q2 K9 n
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point., V$ t6 L4 t8 E
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.( ^/ `( I F5 b* X% N+ j% X, j6 `( I
|